Survival differences of patients with treatment-naive CLL between the chemoimmunotherapy and BTKi eras: An eric study.
Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Anna Puiggros(Hospital Del Mar), Ιoannis Kotsianidis(Democritus University of Thrace), Yair Herishanu(Tel Aviv University), Rosa Collado(Hospital General Universitario De Valencia), Εliana Konstantinou(National and Kapodistrian University of Athens), Alessandro Cellini(University of Padua), Ana Muntanola Prat(Vall d'Hebron Institut de Recerca), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alexandros Machairas(Laiko General Hospital of Athens), Antonio Cuneo(University of Ferrara), Rocío García‐Serra(Hospital General Universitario De Valencia), Luca Laurenti(Sapienza University of Rome), Alessandro Gozzetti(University of Siena), Ritu Gupta(Chandigarh University), Leila Perobelli(Dr. Euryclides Hospital de Jesus Zerbini), Celso Arrais‐Rodrigues(Hotel Dieu Hospital), Marta Coscia(University of Turin), Maria Dimou(National and Kapodistrian University of Athens), Darko Antić(University of Belgrade), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Michael Doubek(Central European Institute of Technology), Eleftheria Hatzimichael(Thomas Jefferson University), Rocio Nieves Salgado Sanchez(Hospital Universitario Fundación Jiménez Díaz), Mark Catherwood(University of Ulster), Zadie Davis(Royal Bournemouth Hospital), Blanca Espinet(Hospital Del Mar), Maria Kislova(Botkin Hospital), Roberta Murru, Carlos Chiattone(Faculdade de Ciências Médicas da Santa Casa de São Paulo), Gerassimos A. Pangalis(Athens Medical Center), Šárka Pospı́šilová(Central European Institute of Technology), Eva Minga(Centre for Research and Technology Hellas), Maria K. Angelopoulou(Laiko General Hospital of Athens), Ozren Jakšić(University of Zagreb), Maria Efstathopoulou(Mansoura University), Samir Mouhssine(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sophia Chatzileontiadou(AHEPA University Hospital), Andreas Epameinondas Koumpis(University of Ioannina), Maria Papaioannou(AHEPA University Hospital), Francesca Martini(University of Pisa), Maya Koren Michowitz(Assaf Harofeh Medical Center), Marta Campreciós Crespo(Universitat Autònoma de Barcelona), Miguel Argüello De Tomás(Universitat Autònoma de Barcelona), Caterina Chessa, Šárka Pavlová(Central European Institute of Technology), Marcello Bradaschia(University of Siena), Persefoni Talimtzi(Centre for Research and Technology Hellas)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
|The Lancet|2007|679
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378